The past decade has seen a relatively constant rate of newly approved drugs every year. The number has even jumped in the past few years. Yet, despite such encouraging trends, we are actually facing a crisis in drug innovation today. That is because many...
Filed under: Medicare, Pharma, Cost, Health Policy Lab, Medicaid and CHIP, drugs, Drugs and Medical Technology, legislation, NIH, Marketing, price, FDA, Medical Innovation Act, medical innovation, corporations